Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review

References

• Leung AKC, Lam JM, Leong KF, Hon KL. Pityriasis Rosea: an updated review. Curr Pediatr Rev. 2021;17(3):201–211. doi:10.2174/1573396316666200923161330
   Web of Science ®Google Scholar
• Villalon-Gomez JM. Pityriasis Rosea: diagnosis and treatment. Am Fam Physician. 2018;97(1):38–44.
   PubMed Web of Science ®Google Scholar
• Litchman G, Nair PA, Le JK Pityriasis Rosea; 2023.
   Google Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Urbina F, Das A, Sudy E. Clinical variants of pityriasis rosea. World J Clin Cases. 2017;5(6):203–211. doi:10.12998/wjcc.v5.i6.203
   Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J DermatolTreat. 2022;33(1):592. doi:10.1080/09546634.2020.1769828
   Google Scholar
• Temiz SA, Abdelmaksoud A, Dursun R, Durmaz K, Sadoughifar R, Hasan A. Pityriasis rosea following SARS-CoV-2 vaccination: a case series. J Cosmet Dermatol. 2021;20(10):3080–3084. doi:10.1111/jocd.14372
   PubMed Web of Science ®Google Scholar
• Freeman EE, Sun Q, McMahon DE, et al. Skin reactions to COVID-19 vaccines: an American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type. J Am Acad Dermatol. 2022;86(4):e165–e167. doi:10.1016/j.jaad.2021.11.016
   PubMed Web of Science ®Google Scholar
• Adya KA, Inamadar AC, Albadri W. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male. Dermatol Ther. 2021;34(5):e15040. doi:10.1111/dth.15040
   Web of Science ®Google Scholar
• Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J Med Virol. 2022;94(3):814–816. doi:10.1002/jmv.27364
   Web of Science ®Google Scholar
• Buckley JE, Landis LN, Rapini RP. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: a case report and review of the literature. JAAD Int. 2022;7:164–168. doi:10.1016/j.jdin.2022.01.009
   PubMedGoogle Scholar
• Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis. 2022;10(2):265–271. doi:10.1002/iid3.568
   PubMed Web of Science ®Google Scholar
• Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. Br J Dermatol. 2021;185(2):e34. doi:10.1111/bjd.20143
   PubMed Web of Science ®Google Scholar
• Cohen OG, Clark AK, Milbar H, Tarlow M. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Hum Vaccin Immunother. 2021;17(11):4097–4098. doi:10.1080/21645515.2021.1963173
   PubMed Web of Science ®Google Scholar
• Das P, Arora S, Singh GK, et al. A study of COVID-19 vaccine (Covishield) induced dermatological adverse effects from India. J Eur Acad Dermatol Venereol. 2022;36(6):e402–e404. doi:10.1111/jdv.17951
   Web of Science ®Google Scholar
• Dormann H, Grummt S, Karg M. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19. Dtsch Arztebl Int. 2021;118(25):431. doi:10.3238/arztebl.m2021.0257
   PubMedGoogle Scholar
• Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34–41. doi:10.1111/cup.14104
   Web of Science ®Google Scholar
• Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case Report: pityriasis rosea-like eruption following COVID-19 vaccination. Front Med. 2021;8:752443. doi:10.3389/fmed.2021.752443
   Web of Science ®Google Scholar
• Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–152. doi:10.1111/bjd.20639
   PubMed Web of Science ®Google Scholar
• Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesqué D, Giménez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e721–e722. doi:10.1111/jdv.17498
   Web of Science ®Google Scholar
• Mehta H, Handa S, Malhotra P, et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022;36(1):e16–e18. doi:10.1111/jdv.17678
   Web of Science ®Google Scholar
• Niebel D, Wenzel J, Wilsmann-Theis D, Ziob J, Wilhelmi J, Braegelmann C. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines. Dermatopathol. 2021;8(4):463–476. doi:10.3390/dermatopathology8040049
   PubMed Web of Science ®Google Scholar
• Pedrazini MC, Groppo FC. L-lysine therapy to control the clinical evolution of pityriasis rosea: clinical case report and literature review. Dermatol Ther. 2021;34(1):e14679. doi:10.1111/dth.14679
   Web of Science ®Google Scholar
• Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination. Int J Infect Dis IJID off Publ Int Soc Infect Dis. 2022;114:88–89. doi:10.1016/j.ijid.2021.10.055
   PubMed Web of Science ®Google Scholar
• Tihy M, Menzinger S, André R, Laffitte E, Toutous-Trellu L, Kaya G. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines. J Eur Acad Dermatol Venereol. 2021;35(12):2456–2461. doi:10.1111/jdv.17633
   Web of Science ®Google Scholar
• Valk B, Bender B. Pityriasis rosea associated with COVID-19 vaccination: a common rash following administration of a novel vaccine. Cutis. 2021;108(6):317–318. doi:10.12788/cutis.0411
   PubMed Web of Science ®Google Scholar
• Wang CS, Chen HH, Liu SH. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formos Med Assoc. 2022;121(5):1003–1007. doi:10.1016/j.jfma.2021.12.028
   PubMed Web of Science ®Google Scholar
• Yu JN, Angeles CB, Lim HG, Chavez C, Roxas-Rosete C. Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines. J Eur Acad Dermatol Venereol. 2021;35(12):e841–e845. doi:10.1111/jdv.17575
   Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–121. doi:10.1016/j.jaad.2021.09.002
   PubMed Web of Science ®Google Scholar
• Vastarella M, Picone V, Martora F, Fabbrocini G. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. J Eur Acad Dermatol Venereol. 2021;35(12):e845–e846. doi:10.1111/jdv.17576
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. J Eur Acad Dermatol Venereol. 2021;35(8):e489–e491. doi:10.1111/jdv.17301
   PubMed Web of Science ®Google Scholar
• Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;35(9):e546–e548. doi:10.1111/jdv.17342
   Web of Science ®Google Scholar
• Farinazzo E, Ponis G, Zelin E, et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol. 2021;35(9):e548–e551. doi:10.1111/jdv.17343
   Web of Science ®Google Scholar
• Khattab E, Christaki E, Pitsios C. Pityriasis Rosea Induced by COVID-19 Vaccination. Eur J Case Rep Intern Med. 2022;9(2):3164. doi:10.12890/2022_003164
   Google Scholar
• Abdullah L, Hasbani D, Kurban M, Abbas O. Pityriasis rosea after mRNA COVID-19 vaccination. Int J Dermatol. 2021;60(9):1150–1151. doi:10.1111/ijd.15700
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. doi:10.1111/ced.152861
   Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2). doi:10.3390/v13020202
   Web of Science ®Google Scholar
• Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1–9. doi:10.1016/j.virol.2020.08.011
   PubMed Web of Science ®Google Scholar
• Hwang JK, Del Toro NP, Han G, Oh DH, Tejasvi T, Lipner SR. Review of Teledermatology: lessons Learned from the COVID-19 Pandemic. Am J Clin Dermatol. 2023. doi:10.1007/s40257-023-00826-z
   Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Invest Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a review of the current literature. Clin Cosmet Invest Dermatol. 2022;15:2369–2382. doi:10.2147/CCID.S388245
   PubMed Web of Science ®Google Scholar
• Hadj Hassine I. Covid-19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32(4):e2313. doi:10.1002/rmv.2313
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28(2):202–221. doi:10.1016/j.cmi.2021.10.005
   PubMed Web of Science ®Google Scholar
• Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the evidence says “less fear”. J Cosmet Dermatol. 2023;22(1):28–29. doi:10.1111/jocd.15533
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to “Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study”. by Bawane J et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18341
   Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic. J Eur Acad Dermatol Venereol. 2020;34:6.
   Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J DermatolTreat. 2022:1–6. doi:10.1080/09546634.2022.2102121
   Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9). doi:10.3390/jcm12093233
   Web of Science ®Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi:10.1080/14740338.2022.1993819
   PubMed Web of Science ®Google Scholar
• Behan JW, Sutton A, Wysong A. Management of skin cancer in the high-risk patient. Curr Treat Options Oncol. 2016;17(12):60. doi:10.1007/s11864-016-0435-z
   Web of Science ®Google Scholar
• Tagliaferri L, Di Stefani A, Schinzari G, et al. Skin cancer triage and management during COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020;34(6):1136–1139. doi:10.1111/jdv.16529
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G, Fornaro L, Guerrasio G, Potestio L. Effects of COVID-19 pandemic on malignant melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023;37(1):e22–e23. doi:10.1111/jdv.18545
   PubMed Web of Science ®Google Scholar
• Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: a systematic review. Immun Inflamm Dis. 2023;11(4):e804. doi:10.1002/iid3.804
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865.
   Web of Science ®Google Scholar
• Kricorian K, Civen R, Equils O. COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety. Hum Vaccin Immunother. 2022;18(1):1950504. doi:10.1080/21645515.2021.1950504
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022. doi:10.1111/ced.15395
   Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15331
   Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Wong N, Cascardo CA, Mansour M, Qian V, Potts GA. A review of pityriasis rosea in relation to SARS-CoV-2/COVID-19 infection and vaccination. Cureus. 2023;15(5):e38772. doi:10.7759/cureus.38772
   Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282.
   PubMed Web of Science ®Google Scholar